This site is intended for healthcare professionals only
LoginRegister

Torrent Pharma: USFDA concludes inspection at Vizag facility with zero observations

Written By : Ruchika Sharma |Medically Reviewed By : Dr. Kamal Kant Kohli   |  
Torrent Pharma: USFDA concludes inspection at Vizag facility with zero observations
  • whatsapp
  • Telegram

Ahmedabad: Torrent Pharma has announced that the U.S. Food and Drug Administration (USFDA) has concluded an inspection at the company's manufacturing facility at Vizag, Andhra Pradesh with zero observations.

The facility was inspected from 28-Jul-25 to 01-Aug-25.

Read also: Torrent Pharma seeks CCI clearance to acquire majority stake in JB Pharma in Rs 19500 crore deal

This week, Medical Dialogues team also reported that the company is preparing to introduce both oral and injectable versions of Semaglutide, a blockbuster diabetes and weight loss drug, currently led by Danish pharmaceutical giant Novo Nordisk, following its patent expiry in India in early 2026.

Read also: Torrent Pharma Gears Up to Launch Oral, Injectable Semaglutide in 2026 Post Patent Expiry: Report

Torrent Pharmaceuticals, headquartered in Ahmedabad, Gujarat, is a prominent Indian pharmaceutical company known for developing, manufacturing, and marketing branded and generic medications. It operates across various therapeutic areas, including cardiovascular, central nervous system, and diabetes care, with a strong presence in both regulated and emerging global markets.

Read also: Intas Pharma appoints Umesh Gupta as Associate Executive Vice President - Manufacturing Operations

torrent pharmatorrent pharma newsUSFDAUSFDA inspection
Ruchika Sharma
Ruchika Sharma

    Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    X